Multiple epitope fusion protein
View Patent ↗Multiple epitope fusion proteins and immunoassays using the same are disclosed. The multiple epitope fusion proteins are encompassed by the general structural formula (A) x −(B) y −C 2 which represents a linear amino acid sequence, wherein B is an amino acid sequence of an epitope or cluster of epitopes and each B contains at least five and not more than 1,000 amino acids, y is an integer of 2 or more, A and C are each independently an amino acid sequence of an epitope or cluster of epitopes not adjacent to B in nature and x and z are each independently an integer of 0 or more wherein at least one of x and z is 1 or more.
1. A method for detecting antibodies to hepatitis C virus (HCV) in a biological sample suspected of containing antibodies, the method comprising the steps of
contacting said sample with a multiple copy epitope sequence comprising the general structural formula (I):
(A) x −(B) y −(C) z (I)
wherein (I) is a linear amino acid sequence;
(B) is an amino acid sequence containing at least five and not more than 1,000 amino acids which amino acids correspond to a naturally occurring antigenic determinant of a hepatitis C virus (HCV) polyprotein;
(A) and (C) are each amino acid sequences different from (B) and different from each other and are each independently an amino acid sequence containing at least five and not more than 1,000 amino acids which amino acids represent an antigenic determinant that is not adjacent to (B) in naturally-occurring strains of HCV;
x is an integer of 2 or more and at least two (A)s are the same antigenic determinant from the same HCV strain;
y is an integer of 2 or more and at least two (B)s are the same or an equivalent antigenic determinant from different HCV strains; and wherein (A), (B) and (C) are in any linear order; under conditions that permit antibody-antigen reaction; and
detecting the presence of immune complexes of said antibodies and said antigens.
2. The method of claim 1 , wherein (A), (B), and (C) are epitopes from a single organism.
3. The method of claim 1 , wherein (A), (B), and (C) are epitopes from 2 organisms.
4. The method of claim 1 , wherein y is 2 or more and at least one (B) is an equivalent antigenic determinant from a different strain of said organism.
5. The method of claim 1 , wherein copies of any one or more of(A), (B), and (C) are identical amino acid sequences when any one or more of x, y and z are greater than 1.
6. The method of claim 1 , wherein (A), (B), and (C) are in a linear order that is different from the linear order of the naturally occurring antigenic determinants.
7. The method of claim 1 , wherein y is 3 and wherein one (B) is an equivalent antigenic determinant from a hepatitis C strain selected from the group consisting of HCV-1, HCV-2, and HCV-3.
8. The method of claim 1 , wherein (A), (B), and (C) are epitopes of a hepatitis C virus, wherein y is 3 and wherein each (B) is an equivalent antigenic determinant from HCV-1, HCV-2, and HCV-3.
9. The method of claim 8 , wherein x is 2 and each (A) is an epitope from the core region of the HCV polyprotein.
10. The method of claim 8 , wherein each (B) is an epitope from the 5-1-1 region of the HCV polyprotein and x is 2, and each (A) is an epitope from the core region of the HCV polyprotein.
11. The method of claim 8 , wherein (B) is an epitope from the 5-1-1 region of the HCV polyprotein and z is 2, and each (C) is an epitope from the core region of the HCV polyprotein.
12. The method of claim 1 , wherein (B) is from the NS3 region of an HCV polyprotein.
13. The method of claim 1 , wherein z is not zero.
14. The method of claim 1 , wherein any of (A), (B), and (C) are separated by one or more amino acids.
15. The method of claim 14 , wherein (A), (B), and (C) are separated by one or more amino acid sequences containing at least five and not more than 1,000 amino acids, which amino acids correspond to an antigenic determinant, and wherein (A), (B), and (C) are not positioned relative to each other in this manner in nature.
16. The method of claim 1 , wherein (A), (B), and (C), are epitopes from regions of the HCV polyprotein, wherein said regions are selected from the group consisting of NS3, NS4, NS5, c100, C25, core, E1, E2, c33c, c100-3, and c22.
17. The method of claim 1 , wherein the multiple epitope polypeptide comprises the formula of the MEFA-3 antigen as depicted in FIG. 1 .
18. The method of claim 1 , wherein the multiple epitope polypeptide comprises the formula of the MEFA-5 antigen as depicted in FIG. 1 .
19. The method of claim 1 , wherein the multiple epitope polypeptide comprises the formula of the MEFA-6 antigen as depicted in FIG. 1 .
20. The method of claim 1 , further comprising the step of coating the multiple epitope polypeptide on a surface of a solid matrix.
21. The method of claim 20 , wherein the solid matrix is selected from the group consisting of the surface of a microtiter plate well, a bead and a dipstick.
22. The method of claim 1 , further comprising the step of attaching a detectable marker to the multiple epitope polypeptide.
23. The method of claim 22 , wherein the detectable marker is selected from the group consisting of a chromophore, an antibody, an antigen, an enzyme, an enzyme reactive compound whose cleavage produce is detectable, biotin, streptavidin, a fluorescent compound, a chemiluminescent compound and combinations thereof.
24. The method of claim 1 , wherein said antibody-antigen complexes are detected by incubating the complexes with a labeled anti-human immunoglobulin antibody.
25. The method of claim 24 , wherein said anti-human immunoglobulin is enzyme labeled.
26. The method of claim 1 , wherein said biological sample is selected from human blood, serum or plasma.
27. The method of claim wherein 1 , said multiple epitope polypeptide is prepared by chemical synthesis.
28. The method of claim 1 , wherein said multiple epitope polypeptide is prepared by recombinant DNA expression.